Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
Beatriz Aranda-Orgillés(Intellicell Biosciences (United States)), Laurent Poirot(Epigénétique et Destin Cellulaire)
Cited by 9
Related Papers
An oxygen sensitive self-decision making engineered CAR T-cell
|Scientific Reports|2017|223
Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
|Frontiers in Immunology|2023|50
Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer
|Science Advances|2024|33
Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
|bioRxiv (Cold Spring Harbor Laboratory)|2023|2